Анализ сетей коэкспрессии генов и белок–белковых взаимодействий с участием натрий-зависимого фосфатного транспортера NaPi2b в нормальных и опухолевых тканях яичника

Исследование посвящено сравнительному анализу сетей коэкспрессии гена SLC34A2 натрий-зависимого фосфатного транспортера NaPi2b с генами гликозил- и сульфотрансфераз и взаимодействия продуктов этих генов в нормальных и опухолевых клетках яичника для выявления белков, ответственных за аберрантное гликозилирование транспортера NaPi2b при злокачественной трансформации клеток. Данные по экспрессии 214 генов гликозил- и сульфотрансфераз и гена SLC34A2 в нормальных и опухолевых клетках были получены из исследования E-MTAB-3732 (ArrayExpress, n = 579), а данные о 7025 белок–белковых взаимодействиях из открытых баз данных. Построенные на основе собранных данных сети показали различия в паттернах коэкспрессии генов и взаимодействия их продуктов. Коэффициент кофенетической корреляции сетей в нормальных и опухолевых клетках яичника составил 0.17. Ключевые гены B3GNT2, GCNT1, ST3GAL1, ST6GAL1 входят в состав крупнейшего модуля вместе с геном SLC34A2 в сети коэкспрессии генов и белок–белковых взаимодействий в опухолях. Сделано предположение, что профили экспрессии и взаимодействий продуктов генов ST6GAL1, B3GNT2, GCNT1, ST3GAL1 могут быть связаны с аномальным гликозилированием NaPi2b в опухолевых клетках. Дальнейшие исследования этих белков важны для понимания роли гликозилирования в изменениях конформации большого внеклеточного домена транспортера NaPi2b и разработки противоопухолевых препаратов против потенциального опухоль-специфического эпитопа МХ35 транспортера NaPi2b.

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015. V. 136, No 5. P. E359–E386. https://doi.org/10.1002/ijc.29210.

2. Bookman M.A. Can we predict who lives long with ovarian cancer? // Cancer. 2019. V. 125, No S24. P. 4578–4581. https://doi.org/10.1002/cncr.32474.

3. Nurgalieva A.K., Popov V.E., Skripova V.S., Bulatova L.F., Savenkova D.V., Vlasenkova R.A., Safina S.Z., Shakirova E.Zh., Filonenko V.V., Bogdanov M.V., Kiyamova R.G. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer // Biochem. Biophys. Rep. 2021. V. 28. Art. 101104. https://doi.org/10.1016/j.bbrep.2021.101104.

4. Zhang M., Cheng S., Jin Y., Zhao Y., Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer // Biochim. Biophys. Acta, Rev. Cancer. 2021. V. 1875, No 2. Art. 188503. https://doi.org/10.1016/j.bbcan.2021.188503.

5. Yedema C., Massuger L., Hilgers J., Servaas J., Poels L., Thomas C., Kenemans P. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays // Int. J. Cancer. 1988. V. 3, No S3. P. 61–67. https://doi.org/10.1002/ijc.2910410813.

6. Negishi Y., Iwabuchi H., Sakunaga H., Sakamoto M., Okabe K., Sato H., Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients // Gynecol. Oncol. 1993. V. 48, No 2. P. 148–154. https://doi.org/10.1006/gyno1993.1026.

7. Gadducci A., Cosio S., Carpi A., Nicolini A., Genazzani A.R. Serum tumor markers in the management of ovarian, endometrial and cervical cancer // Biomed. Pharmacother. 2004. V. 58, No 1. P. 24–38. https://doi.org/10.1016/j.biopha.2003.11.003.

8. Li J., Dowdy S., Tipton T., Podratz K., Lu W.-G., Xie X., Jiang S.-W. HE4 as a biomarker for ovarian and endometrial cancer management // Expert Rev. Mol. Diagn. 2009. V. 9, No 6. P. 555–566. https://doi.org/10.1586/erm.09.39.

9. Morand S., Devanaboyina M., Staats H., Stanbery L., Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine // Int. J. Mol. Sci. 2021. V. 22, No 12. Art. 6532. https://doi.org/10.3390/ijms22126532.

10. Kiyamova R.G., Gryshkova V.S., Usenko V.S., Khozaenko Y.S., Gurtovyy V.A., Yin B., Ritter G., Old L., Gout I.T., Filonenko V.V. Identification of phosphate transporter Napi2b as MX35 cancer antigen by modified SEREX approach // Biopolym. Cell. 2008. V. 24, No 3. P. 218–224. https://doi.org/10.7124/bc.0007a3.

11. Yin B.W.T., Kiyamova R., Chua R., Caballero O.L., Gout I., Gryshkova V., Bhaskaran N., Souchelnytskyi S., Hellman U., Filonenko V., Jungbluth A.A., Odunsi K., Lloyd K.O., Old L.J., Ritter G. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas // Cancer Immunol. Res. 2008. V. 8, No 1. Art. 3. https://doi.org/10.1158/1424-9634.DCL-3.8.1.

12. Xu H., Bai L., Collins J.F., Ghishan F.K. Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodiumphosphate (Na+–Pi) transporter (SLC34A2) // Genomics. 1999. V. 62, No 2. P. 281–284. https://doi.org/10.1006/geno.1999.6009.

13. Wang Y., Yang W., Pu Q., Yang Y., Ye S., Ma Q., Ren J., Cao Z., Zhong G., Zhang X., Liu L., Zhu W. The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer // J. Biomed. Sci. 2015. V. 22, No 1. Art. 52. https://doi.org/10.1186/s12929-015-0158-7.

14. Shyian M., Gryshkova V., Kostianets O., Gorshkov V., Gogolev Yu., Goncharuk I., Nespryadko S., Vorobjova L., Filonenko V., Kiyamova R. Quantitative analysis of SLC34A2 expression in different types of ovarian tumors // Exp. Oncol. 2011. V. 33, No 2. P. 94–98.

15. Gryshkova V., Goncharuk I., Gurtovyy V., Khozhayenko Yu., Nespryadko S., Vorobjova L., Usenko V., Gout I., Filonenko V., Kiyamova R. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer // Exp. Oncol. 2009. V. 31, No 1. P. 37–42.

16. Vlasenkova R., Nurgalieva A., Akberova N., Bogdanov M., Kiyamova R. Characterization of SLC34A2 as a potential prognostic marker of oncological diseases // Biomolecules. 2021. V. 11, No 12. Art. 1878. https://doi.org/10.3390/biom11121878.

17. Kopantzev E.P., Monastyrskaya G.S., Vinogradova T.V., Zinovyeva M.V., Kostina M.B., Filyukova O.B., Tonevitsky A.G., Sukhikh G.T., Sverdlov E.D. Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma // Lung Cancer. 2008. V. 62, No 1. P. 23–34. https://doi.org/10.1016/j.lungcan.2008.02.011.

18. Yang W., Wang Y., Pu Q., Ye S., Ma Q., Ren J., Zhong G., Liu L., Zhu W. Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells // Mol. Med. Rep. 2014. V. 10, No 3. P. 1205–1214. https://doi.org/10.3892/mmr.2014.2376.

19. Jiang Z., Hao Y., Ding X., Zhang Z., Liu P., Wei X., Xi J. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells // Tumor Biol. 2016. V. 37, No 8. P. 10383–10392. https://doi.org/10.1007/s13277-016-4928-y.

20. Zhao Y., Zhu Z., Shi S., Wang J., Li N. Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis // Biomed. Pharmacother. 2019. V. 120. Art. 109457. https://doi.org/10.1016/j.biopha.2019.109457.

21. Kiyamova R., Shyian M., Lyzogubov V.V., Usenko V.S., Gout T., Filonenko V. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues // Exp. Oncol. 2011. V. 33, No 3. P. 157–161.

22. Chen D.-R., Chien S.-Y., Kuo S.-J., Teng Y.-H., Tsai H.-T., Kuo J.-H., Chung J.-G. SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer // Anticancer Res. 2010. V. 30, No 10. P. 4135–4140.

23. Ge G., Zhou C., Ren Y., Tang X., Wang K., Zhang W., Niu L., Zhou Y., Yan Y., He J. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling // Tumor Biol. 2016. V. 37, No 4. P. 5049–5062. https://doi.org/10.1007/s13277-015-4226-0.

24. Lv Y., Wang T., Fan J., Zhang Z., Zhang J., Xu C., Li Y., Zhao G., He C., Meng H., Yang H., Wang Z., Liu J., Chen J., Wang L. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147+ breast cancer stem cells // Tumor Biol. 2017. V. 39, No 4. Art. 1010428317695927. https://doi.org/10.1177/1010428317695927.

25. Jarząb B., Wiench M., Fujarewicz K., Simek K., Jarząb M., Oczko-Wojciechowska M., Włoch J., Czarniecka A., Chmielik E., Lange D., Pawlaczek A., Szpak S., Gubała E., Świerniak A. Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications // Cancer Res. 2005. V. 65, No 4. P. 1587–1597. https://doi.org/10.1158/0008-5472.CAN-04-3078.

26. Huang F., Wang H., Xiao J., Shao C., Zhou Y., Cong W., Gong M., Sun J., Shan L., Hao Z., Wang L., Ding S., Yu Z., Liu J., Jia H. SLC34A2 up-regulation and SLC4A4 down-regulation correlates with invasion, metastasis, and the MAPK signaling pathway in papillary thyroid carcinomas // J. Cancer. 2021. V. 12, No 18. P. 5439–5453. https://doi.org/10.7150/jca.56730.

27. Hakim S.A., Abd El Atti R.M., Faheim R.M., Abou Gabal H.H. Evaluation of the prognostic value of solute carrier family 34 member 2 “SLC34A2” in papillary thyroid carcinoma: An immunohistochemical study // Anal. Cell. Pathol. 2021. V. 2021. Art. 3198555. https://doi.org/10.1155/2021/3198555.

28. Liu L., Yang Y., Zhou X., Yan X., Wu Z. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer // Biomed. Pharmacother. 2018. V. 99. P. 645–654. https://doi.org/10.1016/j.biopha.2018.01.124.

29. Ye W., Chen C., Gao Y., Zheng Z.-S., Xu Y., Yun M., Weng H.-W., Xie D., Ye S., Zhang J.-X. Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity // Cell Death Dis. 2017. V. 8, No 2. Art. e2581. https://doi.org/10.1038/cddis.2017.13.

30. Bao Z., Chen L., Guo S. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma // J. Cell. Biochem. 2019. V. 120, No 6. P. 10205–10214. https://doi.org/10.1002/jcb.28305.

31. Lindegren S., Andrade L.N.S., Bäck T., Machado C.M.L., Horta B.B., Buchpiguel C., Moro A.M., Okamoto O.K., Jacobsson L., Cederkrantz E., Washiyama K., Aneheim E., Palm S., Jensen H., Tuma M.C.B., Chammas R., Hultborn R., Albertsson P. Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (anti-NaPi2b) and its humanized version Rebmab200 // PLoS One. 2015. V. 10, No 5. Art. e0126298. https://doi.org/10.1371/journal.pone.0126298.

32. Rubin S.C., Kostakoglu L., Divgi C., Federici M.G., Finstad C.L., Lloyd K.O., Larson S.M., Hoskins W.J. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer // Gynecol. Oncol. 1993. V. 51, No 1. P. 61–66. https://doi.org/10.1006/gyno1993.1247.

33. Bulatova L., Savenkova D., Nurgalieva A., Reshetnikova D., Timonina A., Skripova V., Bogdanov M., Kiyamova R. Toward a topology-based therapeutic design of membrane proteins: Validation of NaPi2b topology in live ovarian cancer cells // Front. Mol. Biosci. 2022. V. 9. Art. 895911. https://doi.org/10.3389/fmolb.2022.895911.

34. Kiyamova R., Minigulova L.F., Skripova V., Nurgalieva A., Reshetnikova D., Savinska L., Filonenko V., Bogdanov M. 34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells // Ann. Oncol. 2020. V. 31, No S5. P. S1227–S1228. https://doi.org/10.1016/j.annonc.2020.08.2193.

35. Lin K., Zhang C., Harstad E., Hiraragi H., Solis W., Tsai S.P., Xu K., Hristopoulos M., Venook R., Rubinfeld B., Polakis P. Abstract 5619: Preclinical development of anti-SLC34A2 antibody drug conjugate as a therapeutic for non-small cell lung and ovarian cancers // Cancer Res. 2013. V. 73, No S8. Abstr. 5619. https://doi.org/10.1158/1538-7445.AM2013-5619.

36. Horsley E., Jabeen A., Veillard N., Havenith K., Janghra N., Alves P., Oblette C., Kirby I., Hogg P.W., Zammarchi F., de Haan L., van Berkel P. Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b // Cancer Res. 2024. V. 84, No S6. Abstr. 5085. https://doi.org/10.1158/1538-7445.AM2024-5085.

37. Xiao L., Lian W., Liu Q., Zong Q., Song S., Stann S., Cai J., Xue T. Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors // Cancer Res. 2024. V. 84, No 6. Abstr. 1894. https://doi.org/10.1158/1538-7445.AM2024-1894.

38. Lairson L.L., Henrissat B., Davies G.J., Withers S.G. Glycosyltransferases: Structures, functions, and mechanisms // Annu. Rev. Biochem. 2008. V. 77. P. 521–555. https://doi.org/10.1146/annurev.biochem.76.061005.092322.

39. Schjoldager K.T., Narimatsu Y., Joshi H.J., Clausen H. Global view of human protein glycosylation pathways and functions // Nat. Rev. Mol. Cell Biol. 2020. V. 21, No 12. P. 729–749. https://doi.org/10.1038/s41580-020-00294-x.

40. Negishi M., Pedersen L.G., Petrotchenko E., Shevtsov S., Gorokhov A., Kakuta Y., Pedersen L.C. Structure and function of sulfotransferases // Arch. Biochem. Biophys. 2001. V. 390, No 2. P. 149–157. https://doi.org/10.1006/abbi.2001.2368.

41. Meany D.L., Chan D.W. Aberrant glycosylation associated with enzymes as cancer biomarkers // Clin. Proteomics. 2011. V. 8, No 1. Art. 7. https://doi.org/10.1186/1559-0275-8-7.

42. Langfelder P., Horvath S. WGCNA: An R package for weighted correlation network analysis // BMC Bioinf. 2008. V. 9, No 1. Art. 559. https://doi.org/10.1186/1471-2105-9-559.

43. Zhang L., Qian Y. An epithelial-mesenchymal transition-related prognostic model for colorectal cancer based on weighted gene co-expression network analysis // J. Int. Med. Res. 2022. V. 50, No 12. Art. 03000605221140683. https://doi.org/10.1177/03000605221140683.

44. Vlasenkova R., Konysheva D., Nurgalieva A., Kiyamova R. Characterization of cancer/testis antigens as prognostic markers of ovarian cancer // Diagnostics. 2023. V. 13, No 19. Art. 3092. https://doi.org/10.3390/diagnostics13193092.

45. Li X.-T., Zhang J.-T., Yan H.-H., Su J., Cheng M.-L., Sun Q.-H., Zhong W.-Z., Wu Y.-L., Zhang X.-C., Hou J. Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer // Cancer Treat. Res. Commun. 2021. V. 26. Art. 100297. https://doi.org/10.1016/j.ctarc.2020.100297.

46. Shukla V., Mallya S., Adiga D., Sriharikrishnaa S., Chakrabarty S., Kabekkodu S.P. Bioinformatic analysis of miR-200b/429 and hub gene network in cervical cancer // Biochem. Genet. 2023. V. 61, No 5. P. 1898–1916. https://doi.org/10.1007/S10528-023-10356-2.

47. Torrente A., Lukk M., Xue V., Parkinson H., Rung J., Brazma A. Identification of cancer related genes using a comprehensive map of human gene expression // PLoS One. 2016. V. 11, No 6. Art. e0157484. https://doi.org/10.1371/journal.pone.0157484.

48. Athar A., Füllgrabe A., George N., Iqbal H., Huerta L., Ali A., Snow C., Fonseca N.A., Petryszak R., Papatheodorou I., Sarkans U., Brazma A. ArrayExpress update – from bulk to single-cell expression data // Nucleic Acids Res. 2019. V. 47. No D1. P. D711–D715. https://doi.org/10.1093/nar/gky964.

49. Haider S., Ballester B., Smedley D., Zhang J., Rice P., Kasprzyk A. BioMart Central Portal— unified access to biological data // Nucleic Acids Res. 2009. V. 37, No S2. P. W23–W27. https://doi.org/10.1093/nar/gkp265.

50. The Gene Ontology Consortium. The Gene Ontology resource: 20 years and still GOing strong // Nucleic Acids Res. 2019. V. 47, No D1. P. D330–D338. https://doi.org/10.1093/nar/gky1055.

51. Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N.T., Morris J.H., Bork P., Jensen L.J., von Mering C. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets // Nucleic Acids Res. 2019. V. 47, No D1. P. D607–D613. https://doi.org/10.1093/nar/gky1131.

52. Kanehisa M., Furumichi M., Tanabe M., Sato Y., Morishima K. KEGG: New perspectives on genomes, pathways, diseases and drugs // Nucleic Acids Res. 2017. V. 45, No D1. P. D353–D361. https://doi.org/10.1093/nar/gkw1092.

53. Haw R.A., Croft D., Yung C.K., Ndegwa N., D’Eustachio P., Hermjakob H., Stein L.D. The Reactome BioMart // Database. 2011. V. 2011. Art. bar31. https://doi.org/10.1093/database/bar031.

54. Agrawal A., Balcı H., Hanspers K., Coort S.L., Martens M., Slenter D.N., Ehrhart F., Digles D., Waagmeester A., Wassink I., Abbassi-Daloii T., Lopes E.N., Iyer A., Acosta J.M., Willighagen L.G., Nishida K., Riutta A., Basaric H., Evelo C.T., Willighagen E.L., Kutmon M., Pico A.R. WikiPathways 2024: Next generation pathway database // Nucleic Acids Res. 2024. V. 52, No D1. P. D679–D689. https://doi.org/10.1093/nar/gkad960.

55. Paysan-Lafosse T., Blum M., Chuguransky S., Grego T., Pinto B.L., Salazar G.A., Bileschi M.L., Bork P., Bridge A., Colwell L., Gough J., Haft D.H., Letunić I., Marchler-Bauer A., Mi H., Natale D.A., Orengo C.A., Pandurangan A.P., Rivoire C., Sigrist C.J.A., Sillitoe I., Thanki N., Thomas P.D., Tosatto S.C.E., Wu C.H., Bateman A. InterPro in 2022 // Nucleic Acids Res. 2023. V. 51, No D1. P. D418–D427. https://doi.org/10.1093/nar/gkac993.

56. Finn R.D., Coggill P., Eberhardt R.Y., Eddy S.R., Mistry J., Mitchell A.L., Potter S.C., Punta M., Qureshi M., Sangrador-Vegas A., Salazar G.A., Tate J., Bateman A. The Pfam protein families database: Towards a more sustainable future // Nucleic Acids Res. 2016. V. 44, No D1. P. D279–D285. https://doi.org/10.1093/nar/gkv1344.

57. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data // Cancer Discovery. 2012. V. 2, No 5. P. 401–404. https://doi.org/10.1158/2159-8290.CD-12-0095.

58. Hao Y., Créquer-Grandhomme A., Javier N., Singh A., Chen H., Manzanillo P., Lo M.-C., Huang X. Structures and mechanism of human glycosyltransferase β1,3-N-acetylglucosaminyltransferase 2 (B3GNT2), an important player in immune homeostasis // J. Biol. Chem. 2021. V. 296. Art. 100042. https://doi.org/10.1074/jbc.RA120.015306.

59. Ali M.F., Chachadi V.B., Petrosyan A., Chengs P.-W. Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling Golgi localization of core 2 N-acetylglucosaminyltransferase 1 // J. Biol. Chem. 2012. V. 287, No 47. P. 39564–39577. https://doi.org/10.1074/jbc.M112.346528.

60. Ortiz-Soto M.E., Reising S., Schlosser A., Seibel J. Structural and functional role of disulphide bonds and substrate binding residues of the human beta-galactoside alpha-2,3-sialyltransferase 1 (hST3Gal1) // Sci. Rep. 2019. V. 9, No 1. Art. 17993. https://doi.org/10.1038/s41598-019-54384-8.

61. GC S., Bellis S.L., Hjelmeland A.B. ST6Gal1: Oncogenic signaling pathways and targets // Front. Mol. Biosci. 2022. V. 9. Art. 962908. https://doi.org/10.3389/fmolb.2022.962908.

62. Wichert B., Milde-Langosch K., Galatenko V., Schmalfeldt B., Oliveira-Ferrer L. Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer // Glycobiology. 2018. V. 28, No 11. P. 898–903. https://doi.org/10.1093/glycob/cwy065.

63. Garnham R., Scott E., Livermore K.E., Munkley J. ST6GAL1: A key player in cancer // Oncol. Lett. 2019. V. 18, No 2. P. 983–989. https://doi.org/10.3892/ol.2019.10458.

64. Anugraham M., Jacob F., Nixdorf S., Everest-Dass A.V., Heinzelmann-Schwarz V., Packer N.H. Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: Glycan structures reflect gene expression and DNA methylation status // Mol. Cell. Proteomics. 2014. V. 13, No 9. P. 2213–2232. https://doi.org/10.1074/mcp.m113.037085.

65. Wu X., Zhao J., Ruan Y., Sun L., Xu C., Jiang H. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer // Cell Death Dis. 2018. V. 9, No 11. Art. 1102. https://doi.org/10.1038/s41419-018-1101-0.

66. Fan T.-c., Yeo H.L., Hsu H.-M., Yu J.-C., Ho M.-Y., Lin W.-D., Chang N.-C., Yu J., Yu A.L. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells // Cancer Lett. 2018. V. 434. P. 184–195. https://doi.org/10.1016/j.canlet.2018.07.026.

67. Tajadura-Ortega V., Gambardella G., Skinner A., Halim A., Van Coillie J., Schjoldager K.T.-B.G., Beatson R., Graham R., Achkova D., Taylor-Papadimitriou J., Ciccarelli F.D., Burchell J.M. O-linked mucin-type glycosylation regulates the transcriptional programme downstream of EGFR // Glycobiology. 2021. V. 31, No 3. P. 200–210. https://doi.org/10.1093/glycob/cwaa075.

68. Tsai H.-E., Chen C.-L., Chang T.-T., Fu C.-W., Chen W.-C., Perez S.J.L.P., Hsiao P.-W., Tai M.-H., Li W.-S. Development of a novel, potent, and selective sialyltransferase inhibitor for suppressing cancer metastasis // Int. J. Mol. Sci. 2024. V. 25, No 8. Art. 4283. https://doi.org/10.3390/ijms25084283.

69. Seagle B.-L.L., Eng K.H., Yeh J.Y., Dandapani M., Schiller E., Samuelson R., Odunsi K., Shahabi S. Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer // Sci. Rep. 2016. V. 6. Art. 21591. https://doi.org/10.1038/srep21591.

70. Sato T., Yoneyama T., Tobisawa Y., Hatakeyama S., Yamamoto H., Kojima Y., Mikami J., Mori K., Hashimoto Y., Koie T., Ohyama C. Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness // Biochem. Biophys. Res. Commun. 2016. V. 470, No 1. P. 150–156. https://doi.org/10.1016/j.bbrc.2016.01.011.

71. Zhuang H., Zhou Z., Zhang Z., Chen X., Ma Z., Huang S., Gong Y., Zhang C., Hou B. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer // Aging. 2020. V. 13, No 2. P. 2310–2329. https://doi.org/10.18632/aging.202255.

72. Zhang W., Hou T., Niu C., Song L., Zhang Y. B3GNT3 expression is a novel marker correlated with pelvic lymph node metastasis and poor clinical outcome in early-stage cervical cancer // PLoS One. 2015. V. 10, No 12. Art. e0144360. https://doi.org/10.1371/journal.pone.0144360.

73. Sun Y., Liu T., Xian L., Liu W., Liu J., Zhou H. B3GNT3, a direct target of miR-149-5p, promotes lung cancer development and indicates poor prognosis of lung cancer // Cancer Manag. Res. 2020. V. 12. P. 2381–2391. https://doi.org/10.2147/CMAR.S236565.

74. Wang Y., Liang N., Xue Z., Xue X. Identifying an eight-gene signature to optimize overall survival prediction of esophageal adenocarcinoma using bioinformatics analysis of ceRNA networ // OncoTargets Ther. 2020. V. 13. P. 13041–13054. https://doi.org/10.2147/OTT.S287084.

75. Lu C.-H., Wu W.-Y., Lai Y.-J., Yang C.-M., Yu L.-C. Suppression of B3GNT7 gene expression in colon adenocarcinoma and its potential effect in the metastasis of colon cancer cells // Glycobiology. 2014. V. 24, No 4. P. 359–367. https://doi.org/10.1093/glycob/cwu002.

76. Čaval, T., Alisson-Silva, F., Schwarz F. Roles of glycosylation at the cancer cell surface: Opportunities for large scale glycoproteomics // Theranostics. 2023. V. 13, No 8. P. 2605–2615. https://doi.org/10.7150/thno.81760.

77. Venkitachalam S., Revoredo L., Varadan V., Fecteau R.E., Ravi L., Lutterbaugh J., Markowitz S.D., Willis J.E., Gerken T.A., Guda K. Biochemical and functional characterization of glycosylationassociated mutational landscapes in colon cancer // Sci. Rep. 2016. V. 6. Art. 23642. https://doi.org/10.1038/srep23642.